Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
NCT ID: NCT02750527
Last Updated: 2021-06-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
13049 participants
OBSERVATIONAL
2016-09-30
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Home Intervention and Social Precariousness in Childhood Diabetes
NCT04530292
Therapeutic Education in Very Young Children With Diabetes Mellitus
NCT01354288
Family Management of Type 1 Diabetes in Children
NCT00273286
Parents' Occupation After Diabetes Onset
NCT04814849
Metabolic Control Adolescents Type 1 Diabetes
NCT05811078
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After study enrolment 200 µl of capillary blood are be taken from the subject and are sent pseudo-anonymized to the lab. LDL-C and the diabetes-associated antibodies are identified. Based on the results a second blood sample will be required. In case of pre-type-1 diabetes or signs for a familial hypercholesterolemia the pediatrician will be informed. He will contact the parents and discuss the further procedure in cooperation with the study center.
In case of a positive result by measuring diabetes-related antibodies and LDL-C the goal of this trial is to advise and educate the families appropriate and to treat them if necessary. In addition families should have the possibility to participate in prevention trials.
All data will be registered in a study database.
Follow-up pre-type 1 diabetes:
During the first year, follow-up will be performed after 6 and 12 months and thereafter annually until the age of 12 years or up to 6 months after the clinical onset of type 1 diabetes.
Follow-up familial hypercholesterolemia:
During the first year, follow-up will be performed after 6 and 12 months and thereafter annually until the age of 12 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 2 and 6 years (both included)
* Written consent by at least one parent / legal representative
* Willingness to deliver 200 µl of capillary blood
* Willingness to complete a questionnaire
* Willingness to participate to the follow-up visits
Exclusion Criteria
2 Years
6 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kinderkrankenhaus auf der Bult
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Olga Kordonouri
Prof. Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Olga Kordonouri, MD
Role: PRINCIPAL_INVESTIGATOR
Kinder- und Jugendkrankenhaus AUF DER BULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-Fr1dolin-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.